MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'investor'. Sat, 03 Sep 2011 02:37:50 +0100 http://www.medworm.com/index.php?rid=4813387&cid=t_118010_112_f&fid=34971&url=http%3A%2F%2Fblog.drmalpani.com%2F2011%2F05%2Flooking-for-healthcare-it-entrepreneurs.html Are you an entrepreneur who wants to improve healthcare in India ? I am an angel investor, and am looking for companies which meet the following criteria.At least 3 years old, with a viable product, who need to grow and scale up and needs funds and a strategic investor to do so. I am especially looking for companies which are active in the following areas: Elearning for healthcareTeaching patients about their health in Indian regional languagesDeveloping healthcare apps customised for IndiaIf you are interested, please send me an email ! (Source: The Patient's Doctor) The Patient's Doctor blogs http://www.medworm.com/rss/comments.php?id=4813387 Thu, 12 May 2011 11:35:00 +0100 4813387 http://www.medworm.com/index.php?rid=4734244&cid=t_118010_112_f&fid=34971&url=http%3A%2F%2Fblog.drmalpani.com%2F2011%2F04%2Fpeas-healthcare-and-patient-education.html While patients in the US are deluged with information, patients in India are usually starved for this. They have to depend upon US websites for information ( much of which is not applicable to Indian conditions and diseases); or upon their doctor ( who is often too busy to educate them !)One of the major issues is that the importance of educating patients has still not become a pressing issue for doctors. Traditionally, Indian doctors have always been quite paternalistic; and most Indian patients are quite happy to follow the doctor's orders.While it's true that times are changing, and that the younger generation of doctors is more willing to be open ad to invest time in discussing treatment options with their patients, another limitation has been the acute shortage of patient educational ... The Patient's Doctor blogs http://www.medworm.com/rss/comments.php?id=4734244 Thu, 21 Apr 2011 03:00:00 +0100 4734244 http://www.medworm.com/index.php?rid=4179522&cid=t_118010_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FAFtgFxHbZMM%2F Given the big patent expirations and thin pipelines, it is hardly surprising that Moody’s Investor Services has issued a report finding that the credit outlook for brand-name drugmakers remains negative for the next 12 to 18 months. More specifically, the ratings agency notes that hurdles for drug approvals remain high, given the ongoing emphasis on safety concerns; various governments are instituting austerity measures to deal with budget deficits and taking a tougher stance on drug price; mergers and acquisitions will continue to be financed with debt; and huge litigation settlements over illegal marketing underscore legal risks. And of course, these negative pressures are expected to remain through 2012, when the biggest patent expirations have largely passed. But as of June, the ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4179522 Thu, 18 Nov 2010 14:11:28 +0100 4179522 http://www.medworm.com/index.php?rid=4098462&cid=t_118010_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FofgMWGHYZdw%2F Today is the day that countless people - from the overweight to those overweighted in Arena Pharmaceutical stock - may learn whether the FDA will approve the drugmaker’s diet pill. Not every agency deadline is so closely watched, but this one is generating enormous attention for two reasons - diet pills have not fared well despite the rising rate of obesity and an unusual push by angry investors who believe the FDA unfairly reviewed the drug - which we were the first to report (see this). Last month, you may recall, an FDA advisory committee voted 9-to-5 that the risks of the Lorqess diet drug developed by Arena outweighed the benefits. The decision came after concerns about valvulopathy and, in particular, links to malignancies in rats at higher doses, which were revealed in FDA bri... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4098462 Fri, 22 Oct 2010 12:57:50 +0100 4098462 http://www.medworm.com/index.php?rid=3471991&cid=t_118010_134_f&fid=34841&url=http%3A%2F%2Fwww.diabetesmine.com%2F2010%2F04%2Fdesign-challenge-outlook-from-the-original-diabetes-entrepreneur.html Robert Oringer is currently Co-Chairman and Board Director of AMG Medical Inc. in Canada, which distributes professional and home healthcare products. But he’s also the man who pioneered private-label diabetes products in the US, including syringes, glucose products, and testing supplies. One might call Robert a serial diabetes entrepreneur — and at least as importantly, father [...] (Source: Diabetes Mine) Diabetes Mine blogs http://www.medworm.com/rss/comments.php?id=3471991 Thu, 15 Apr 2010 13:00:38 +0100 3471991 http://www.medworm.com/index.php?rid=3185563&cid=t_118010_134_f&fid=34841&url=http%3A%2F%2Fwww.diabetesmine.com%2F2010%2F01%2Fchasing-the-omnipod-patch-me-if-you-can.html Last week, I spent a little bit of time at the JP Morgan Healthcare Conference, a nearly-thirty-year-old annual gathering that’s become “the health care industry’s premier financial event, giving more than 330 companies a chance to make formal pitches to institutional investors.”  Due to a houseful of sickies at home, I wasn’t able to attend [...] (Source: Diabetes Mine) Diabetes Mine blogs http://www.medworm.com/rss/comments.php?id=3185563 Tue, 19 Jan 2010 14:00:34 +0100 3185563 http://www.medworm.com/index.php?rid=3089509&cid=t_118010_136_f&fid=37852&url=http%3A%2F%2Fdonnatrussell.com%2F2009%2F12%2F14%2Fstill-have-cash-wall-street-wants-to-talk%2F New cartoon by Trussell & Trussell on AOL’s Politics Daily. Still Have Cash? Wall Street Wants to Talk. Posted in Politics Daily Tagged: chaos theory, economy, gold bubble, meltdown, political cartoon, small investor, wall street (Source: Donna Trussell) Donna Trussell blogs http://www.medworm.com/rss/comments.php?id=3089509 Mon, 14 Dec 2009 18:30:11 +0100 3089509 http://www.medworm.com/index.php?rid=2879476&cid=t_118010_112_f&fid=34971&url=http%3A%2F%2Fdoctorandpatient.blogspot.com%2F2009%2F10%2Fwhy-i-like-being-angel-investor.html I am an angel investor and have invested in 3 startups so far - Inventurus Knowledge Solutions; Yos Technologies; and Plus91.So why do doctors become angel investors ?For one thing, I am curious and enjoy learning. I know lots about IVF ( since I have been doing this for over 20 years now !) and it's fun to learn about new areas and other fields - it helps to keep me young and on my toes !It also helps that I have clever friends who are entrepreneurs and angel investors. Thus, my investment in Inventurus is thanks to Rakesh Jhunjhunwalla ; while the one in Yos is because of Rajesh Jain . ( The Plus91 is my own initiative !)I can use their expertise to get a second opinion on how to evaluate investment opportunities ; and they also provide a sounding board which gives me more confidence in ... The Patient's Doctor blogs http://www.medworm.com/rss/comments.php?id=2879476 Sat, 10 Oct 2009 12:47:00 +0100 2879476 http://www.medworm.com/index.php?rid=1951871&cid=t_118010_134_f&fid=34841&url=http%3A%2F%2Fwww.diabetesmine.com%2F2008%2F11%2Ftesting-testing-a-new-diabetes-rewards-system.html Are you on board with the notion of paying people to do the right things in life? I’m asking because I’m about to announce beta testing of a new diabetes education website that will offer incentives for engagement and progress (that means prizes to you and me). First, a bit about the whole notion of rewards: A [...] (Source: Diabetes Mine) Diabetes Mine blogs http://www.medworm.com/rss/comments.php?id=1951871 Tue, 11 Nov 2008 16:18:16 +0100 1951871 http://www.medworm.com/index.php?rid=1354215&cid=t_118010_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F265599158%2F One of the biggest shareholders in AstraZeneca is questioning the long-term viability of the ‘Big Pharma’ business model by asking whether it could discourage the development of new meds, The Times of London writes. Borje Eckholm, president and chief executive of Investor AB, the Swedish investment group linked to the Wallenberg family that holds a 3.5 per cent stake in AstraZeneca worth more than $2 billion, says a “fundamental question” exists about whether huge, vertically integrated drugmakers make the most effective use of their research funding. “You have to ask yourself: do you have economies of scale in R&D? It’s not clear but one of the fundamental ways that companies create value for shareholders is strong R&D,” he tells the paper. &#8220... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1354215 Mon, 07 Apr 2008 11:21:52 +0100 1354215 http://www.medworm.com/index.php?rid=941985&cid=t_118010_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F168111379%2F So says Moody’s Investor Services in a forthcoming report. Given some of pharma’s challenges, though, this probably isn’t terribly surprising. “Approaching patent expirations between 2010 and 2012, a tougher regulatory climate, and a shift towards more aggressive financial policies create the potential for rating downgrades,” says Moody’s senior vp Mike Levesque, in a statement. Most big US drugmakers rated by Moody’s face “significant” patent expirations between 2010 and 2012. And for most, cumulative patent expirations through 2012 affect more than 40 percent of current revenues - in some cases, more than 50 percent. In a fit of politeness, he aptly notes that pharma “will be challenged to replace maturing products with growth i... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=941985 Wed, 10 Oct 2007 20:54:14 +0100 941985